Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063154 · ClinicalTrials.gov registry record · Phase 2
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00063154 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 51 participants.
The verdict
NCT00063154, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
Interventions
- DRUG Pertuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063154
The ClinicalTrials.gov registry entry for NCT00063154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pertuzumab is the first listed.
NCT00063154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063154 about?
NCT00063154 is a clinical study titled "Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy". The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
What is the current status of trial NCT00063154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2003-07. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00063154?
The interventions under investigation include: Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT00063154?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.